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Abstract
Concern about use of anthrax as a bioweapon prompted development of novel anthrax antitoxins 
for treatment. Clinical guidelines for the treatment of anthrax recommend antitoxin therapy in 
combination with intravenous antimicrobials; however, a large-scale or mass anthrax incident may 
exceed antitoxin availability and create a need for judicious antitoxin use. We conducted a 
systematic review of antitoxin treatment of inhalation anthrax in humans and experimental 
animals to inform antitoxin recommendations during a large-scale or mass anthrax incident. A 
comprehensive search of 11 databases and the FDA website was conducted to identify relevant 
animal studies and human reports: 28 animal studies and 3 human cases were identified. Antitoxin 
monotherapy at or shortly after symptom onset demonstrates increased survival compared to no 
treatment in animals. With early treatment, survival did not differ between antimicrobial 
monotherapy and antimicrobial-antitoxin therapy in nonhuman primates and rabbits. With delayed 
treatment, antitoxin-antimicrobial treatment increased rabbit survival. Among human cases, 
addition of antitoxin to combination antimicrobial treatment was associated with survival in 2 of 
the 3 cases treated. Despite the paucity of human data, limited animal data suggest that adjunctive 
antitoxin therapy may improve survival. Delayed treatment studies suggest improved survival with 
combined antitoxin-antimicrobial therapy, although a survival difference compared with 
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antimicrobial therapy alone was not demonstrated statistically. In a mass anthrax incident with 
limited antitoxin supplies, antitoxin treatment of individuals who have not demonstrated a clinical 
benefit from antimicrobials, or those who present with more severe illness, may be warranted. 
Additional pathophysiology studies are needed, and a point-of-care assay correlating toxin levels 
with clinical status may provide important information to guide antitoxin use during a large-scale 
anthrax incident.
Bacillus anthracis, a Gram-positive and spore-forming bacterium that causes anthrax, is 
considered a high-priority threat because of its widespread availability, easy dissemination, 
and ability to cause substantial morbidity and mortality.1–5 In the United States, Bacillus 
anthracis is a select agent and subject to the select agent regulations (42 CFR Part 73). 
Inhalation anthrax is one of the most lethal forms of anthrax; without treatment, its fatality 
rates range from 92% to almost 100%.6,7 In the 2001 US anthrax incident, antimicrobial 
treatment was associated with a 55% mortality reduction among inhalation anthrax patients,4 
but there is ongoing interest in reducing mortality even further with adjunctive treatments.
Although antimicrobials can effectively eliminate bacteremia, anthrax is a toxin-mediated 
disease, and toxin accumulation is associated with mortality.3,5 In addition to the poly-D-
glutamic acid capsule of B. anthracis, lethal toxin (LT) and edema toxin (ET) represent 
major virulence factors in anthrax pathogenesis. LT inhibits immune function and is 
primarily responsible for vasomotor instability observed in patients with anthrax; ET causes 
cellular and tissue edema.8–10 LT and ET are formed when protective antigen (PA) binds to 
lethal factor (LF) and edema factor (EF), respectively.8–11 Protective antigen is essential to 
toxin formation, promotes intracellular toxin translocation, and is the main target of vaccines 
and antitoxins.10
Two novel antibody-based antitoxins, ABthrax (also known as Raxibacumab) and Anthrax 
Immune Globulin Intravenous (AIGIV, proprietary name Anthrasil) are available in the 
United States Strategic National Stockpile (SNS), and additional antitoxins are being 
investigated.6,10,12–15 Raxibacumab is an IgG1γ monoclonal antibody, and Anthrasil is a 
human IgG polyclonal antibody. Both antitoxins have been approved by the Food and Drug 
Administration (FDA) under the animal rule.16,17 The Centers for Disease Control and 
Prevention (CDC) recommend antitoxin in addition to antimicrobials to treat patients with 
systemic anthrax.18 However, these recommendations apply in situations where antitoxin is 
readily available, and, other than a diagnosis of systemic anthrax, no additional clinical 
parameters guide antitoxin use. During a large-scale or mass anthrax incident in which the 
demand for antitoxin exceeds antitoxin availability, criteria for antitoxin use may change to 
ensure judicious, efficient, and consistent use of the finite supplies of antitoxin stockpiled in 
the SNS. In the absence of human randomized controlled trials, decisions on antitoxin use 
are likely to be based on available data, predominantly from animal studies and human case 
reports.
We conducted a systematic review of animal studies and human reports involving antitoxin 
treatment of inhalation anthrax. The goal of the review was to compile evidence to inform 
antitoxin recommendations during a large-scale or mass anthrax incident in which the 
demand for antitoxin treatment would be anticipated to exceed the supply. Clinical findings 
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and experimental outcomes associated with the timing of antitoxin administration are 
reported in this review.
Methods
Data Sources and Search Strategy
This review follows the methods outlined in the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA).19 A search strategy was developed in conjunction 
with an expert systematic review librarian. Eleven databases were searched from their 
inception to April 2015: Commonwealth Agricultural Bureaux (1973-), Cumulative Index to 
Nursing and Allied Health Literature (1981-), Defense Technical Information Center 
(1950-), EconLit (1886-), Embase (1988-), Federal Research in Progress (1930-), Global 
Health (1910-), MEDLINE (1946-), National Technical Information Service (1964-), Web 
of Science (1980-), World Health Organization (1948-), and WorldCat (1967-). Article types 
that met a priori inclusion criteria were: randomized controlled trials; case-control, cross-
sectional, or observational studies; case reports; and case series involving inhalation anthrax. 
Consistent search terms were used among databases, and searches were restricted to articles 
in English. Search terms are shown in Figure 1. We identified additional studies through 
hand searching of references, communication with subject matter experts, and searches of 
the FDA website.
Study Selection
Relevant articles included both animal studies and human case reports involving antitoxin 
treatment for inhalation anthrax. For articles to be included, they had to contain information 
on the type of antitoxin, dose administered, timing of administration and/or clinical triggers, 
and survival. Additionally, included studies were restricted to those with information on 
antitoxins available in the SNS or currently under development for clinical use. Animal 
studies were restricted to nonhuman primates (NHPs) and rabbits, because the 
pathophysiology of anthrax in these animals is similar to that of anthrax in humans, and 
these models are accepted for licensure of anthrax medical countermeasures under the FDA 
Animal Rule.10,20–25 Animal studies of antitoxin use as anthrax prophylaxis (ie, 
administered prior to spore exposure or shortly after spore exposure) were excluded because 
these antitoxin uses do not represent treatment. Animal studies were included if they 
involved antitoxin administration at: (1) detection of significant increase in body 
temperature (SIBT) or serum protective antigen, which indicate the onset of bacteremia; (2) 
39 hours or more postexposure in nonhuman primates; or (3) 30 hours or more postexposure 
in rabbits. The specific time points were chosen because they represent the average time 
points for the onset of bacteremia following exposure to B. anthracis spores in animal 
species.26,27
Titles and abstracts of relevant articles were reviewed independently by 2 reviewers using a 
priori inclusion criteria. Full-text reviews of articles were then conducted to identify eligible 
studies for data abstraction.
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Data Abstraction and Analysis
An Excel data abstraction tool was developed by 2 systematic reviewers using templates 
from previous anthrax systematic reviews.7,28 Data extracted for animal studies included 
study design, exposure, treatment time points or clinical trigger, type of treatment, and 
survival. For human inhalation anthrax case reports, data extracted included age, sex, 
exposure, clinical presentation, antimicrobial type and administration timing, antitoxin type 
and administration timing, supportive care, and survival. Clinical characteristics documented 
in published case reports were consolidated with unpublished CDC data. The level for 
statistical significance was set at p ≤ 0.05. Because of heterogeneity in study designs, 
analyses, treatment groups, and treatment triggers, we did not perform a meta-analysis.
Results
Search Results
After initial removal of 2,164 duplicate references, 6,178 citations were screened by title and 
abstract. Twenty-two additional citations were identified for review from hand searching of 
references and communication with subject-matter experts. Seventy-seven citations were 
selected for full-text review, and 23 citations met the inclusion criteria. Citations were 
excluded for the following reasons: general reviews of antitoxins, animal studies using 
models other than nonhuman primate and rabbit, animal studies of antitoxin prophylaxis, 
reviews of human anthrax cases that lacked sufficient information for data abstraction, in 
vitro antitoxin studies, studies or cases involving antitoxins that are not available in the SNS 
or under development for clinical use, and human clinical safety trials (Figure 2). Among 
the 23 included citations, 3 human cases of inhalation anthrax treated with antitoxin 
provided relevant clinical and outcome data, and 28 animal studies that involved antitoxin 
treatment provided data on animal survival. The case studies represent low-quality evidence, 
and no widely accepted quality grading schema for extrapolation of animal studies to human 
data exists.
Animal Studies
Antitoxin Monotherapy—Data from 20 animal studies of antitoxin monotherapy are 
summarized in this review. Six antibody-based antitoxins targeting protective antigen were 
included: Anthrasil, Thravixa, Raxibacumab, Anthrivig, Anthim, and Valortim (Table 1). 
Five nonhuman primate studies report the therapeutic effect of antitoxin at various doses and 
administration time points. Studies in which nonhuman primates were treated with antitoxin 
suggested a higher likelihood of survival than those that were untreated or that received a 
placebo. Among nonhuman primates treated at detection of serum PA (31–49 hours 
postexposure), the following were associated with an increase in survival compared to that 
of the controls: Anthrasil at doses 15 U/kg and 30 U/kg; Thravixa at doses of 1 mg/kg, 5 
mg/kg, and 20 mg/kg; and Raxibacumab. Anthrivig survival rates were 2/6 (33.3%), 1/6 
(16.7%), and 2/6 (33.3%) at doses of 7.1, 14.2, and 21.3 mg/kg, respectively, whereas 
survival for controls was 0/6 (0.0%); this difference was not statistically significant.26,29–33 
Among nonhuman primates treated with Anthim 48 hours postexposure, 4/14 (28.6%) 
survived, while 1/10 (10%) survived among the controls.34
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Antitoxin treatment of rabbits at or after the onset of symptoms (detection of either 
significant increase in body temperature or serum PA, whichever occurred first) enhanced 
survival (Table 1). Among rabbits treated with Thravixa, 5/6 (83.3%) survived at the 
detection of significant increase in body temperature, 6/6 (100%) survived at 6 hours post-
SIBT, and 4/5 (80.0%) survived at 12 hours post-SIBT, while none survived in the control 
group; all of these differences were statistically significant.23 Dose-response studies of 
Raxibacumab and Anthrivig demonstrated that treatment at detection of significant increase 
in body temperature or serum PA resulted in 44.4% (8 of 18 treated with 40mg/kg 
Raxibacumab) to 75.0% (6 of 8 treated with 14.2 mg/kg Anthrivig) survival, respectively, 
while none survived among the controls; both of these differences were statistically 
significant.26,29,31 Treatment with Anthrasil demonstrated similar results: 26% survival 
among animals treated compared to 0% survival in the nontreated group, with a statistically 
significant difference between the 2 groups.32,33
Additionally, 8 rabbit studies reported the survival rates after administration of antitoxin at 
36 or 48 hours post-exposure. Survival following administration at 36 hours or 48 hours 
postexposure ranged from 0.0% (0 of 12 treated with 20mg/kg Raxibacumab at 36 h) to 
60.0% (3 of 5 treated with 10 mg/kg Thravixa at 48h). In these 8 studies, only Anthrasil 
(7.5, 15, and 30 U/kg) at 30 h and 10 mg Anthim at 36 h were found to show statistically 
significant differences ( p < 0.05) (Table 1).32,33,35–40
Antitoxin-Antimicrobial Therapy—Eight animal studies compared antimicrobial-
antitoxin therapy to antimicrobial monotherapy. Two studies were conducted in nonhuman 
primates (Table 2). In the Raxibacumab study, treatment was initiated at the detection of 
serum PA, which averaged 42 hours postexposure. Survival proportions for treatment groups 
were 14/14 (100%) in the ciprofloxacin group and 12/14 (85.7%) in the ciprofloxacin-
Raxibacumab group.29 In the Anthrasil study, treatment was initiated at 64 hours 
postexposure. Survival proportions for treatment groups were 75% in the ciprofloxacin 
group and 79% to 83% in ciprofloxacin-Anthrasil groups.32,33
In rabbit studies, survival rates (95%) did not vary between levofloxacin and levofloxacin-
Raxibacumab groups when treatment was initiated at the onset of symptoms (either 
significant increase in body temperature or detection of serum PA, whichever occurred first; 
onset of symptoms occurred on average 28 hours postexposure).29 In addition, at less than 
60 hours, no significant difference in survival rates was observed between levofloxacin-
IVIG and levofloxacin-Anthrasil treatment groups.32 In the most recent rabbit study, 
treatment with doxycycline-Anthim at detection of PA resulted in survival of 9/10 (90%) 
rabbits compared to 5/10 (50%) in the doxycycline alone group ( p = 0.1031).41
Given the similar survival rates of early antimicrobial and antimicrobial-antitoxin treatment, 
additional studies assessed whether adding antitoxin improved survival when treatment was 
delayed. Among 76 (42%) surviving rabbits treated at 84 hours postexposure with 
levofloxacin or levofloxacin-Raxibacumab, 24/37 (65%) survived in the levofloxacin group, 
while 32/39 (82%) survived in the levofloxacin-Raxibacumab group ( p = 0.0874).26,42 
Additional studies were conducted with levofloxacin-Anthrasil at later time points. In one 
study, 18/31 (58%) rabbits treated with levofloxacin-Anthrasil at 96 hours postexpo-sure 
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survived, compared to a 13/33 (39%) survival rate in animals treated with levofloxacin-IVIG 
( p = 0.1353). A similar trend was observed in rabbits treated at 72 or 84 hours 
postexposure, but no significant difference in survival was observed between the treatment 
and control groups (Table 2).27,32,33
Human Case Reports
Limited information was published regarding the 3 inhalation anthrax human cases who 
received Anthrasil treatment (Table 3). B. anthracis was culture-confirmed in all 3 cases. 
Infected individuals were 34 to 61 years old, and all were male. Exposure was known in 2 
patients—animal hide drums—while in 1 case the exposure was not conclusively 
established.43–48 Of the 3 cases, 2 patients survived and 1 died.
All patients demonstrated clinical evidence of sepsis, and all received multidrug intravenous 
antimicrobials at the time of hospital admission.43–48 All patients required mechanical 
ventilation and underwent pleural fluid drainage. One survivor and the nonsurvivor also 
received vasopressors. For all patients, Anthrasil was administered as a single 420-unit dose 
under the CDC-sponsored Investigational New Drug protocol.49
A comparison of the clinical course of survivors and nonsurvivors is presented below. 
Among the 2 survivors, antimicrobials were started 2 to 3 days after symptom onset, and 
Anthrasil was administered 7 or 9 days after symptom onset.45–48 The first survivor initially 
presented with respiratory distress, which progressively worsened despite his receiving 
intravenous antimicrobials. Prior to receiving Anthrasil, he had bilateral pulmonary 
effusions and large amounts of mediastinal fluid requiring drainage by thoracentesis and 
thoracotomy, and he required mechanical ventilation. He also had evidence of multiorgan 
dysfunction as evidenced by progression of pulmonary infiltrates and elevated liver enzymes 
and serum creatinine. He received Anthrasil on day 9 post–symptom onset; however, he 
experienced a reaccumulation of right pleural effusions requiring drainage and then 
subsequently developed acute respiratory distress syndrome. His condition gradually 
improved starting 2 days after Anthrasil administration, with reports of less prominent 
infiltrates on chest radiographs and improved WBC counts over the next several days. He 
was discharged approximately 5 weeks after initial presentation.45,46
The second survivor initially presented with fever, cough, and dyspnea on admission. Prior 
to receiving Anthrasil, he had progressive respiratory failure requiring endotracheal 
intubation, mechanical ventilation, and pleural fluid drainage. The patient received Anthrasil 
7 days post–symptom onset (4 days post–antimicrobial initiation). Two days after Anthrasil 
administration, his condition improved: renal dysfunction, hyponatremia, and 
thrombocytopenia gradually resolved. He was extubated 6 days after Anthrasil 
administration and then discharged approximately 4 weeks after his initial presentation.47,48
Limited information is available on the nonsurvivor. He initially presented to the hospital 
with a 2-day history of fever and rigors, and within 2 days of initial presentation to the 
hospital, he required mechanical ventilation. Antimicrobial therapy was initiated at 
admission. Prior to receiving Anthrasil, he had multisystem organ failure requiring 
mechanical ventilation, vasopressor support, and bilateral pleural fluid drainage (CDC 
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unpublished data). Anthrasil was administered 8 days post–symptom onset. Despite 
administration of Anthrasil, the patient remained in critical condition and died 6 days after 
Anthrasil administration.43,44
Lethal factor levels were measured in all patients, and similar patterns were observed. Serum 
and pleural fluid lethal factor levels declined with antimicrobial use, followed by a faster 
decline after Anthrasil administration. For the first survivor, the lethal factor levels 
decreased steadily from 294.30 ng/mL (3 days post–symptom onset) to 16.0 ng/mL (9 days 
post–symptom onset) with 6 days of antimicrobial treatment prior to Anthrasil 
administration, and decreased further to 0.85 ng/mL 1 hour post-Anthrasil administration.46 
For the second survivor, the lethal factor levels decreased from 58.0 ng/mL (2 days post–
symptom onset) to 1.5 ng/mL (7 days post–symptom onset) with 5 days of antimicrobial 
treatment prior to Anthrasil administration, and decreased further to 0.02 ng/mL within a 
day post–Anthrasil administration.48 For the nonsurvivor, the lethal factor levels declined 
more slowly 12 hours post–Anthrasil administration compared to those of the survivors.50 
Of note, the absolute values of initial serum lethal factor and pleural fluid lethal factor levels 
were much lower in the nonsurvivor, and his first sample was obtained 6 days post–
antimicrobial initiation, whereas the first samples of the survivors were obtained prior to 
antimicrobial initiation.51 Based on measurements of anti-PA, the 2 survivors developed a 
quantifiable antibody response prior to AIGIV administration, and the first survivor was 
fully seroconverted (>4-fold change in anti-PA IgG concentration).46,48
Discussion
Animal studies that evaluate the treatment of inhalation anthrax had small numbers but 
suggest that both antimicrobial monotherapy and antimicrobial-antitoxin therapy at or 
shortly after symptom onset are associated with survival. However, when the treatment is 
delayed 60 hours or more, improved survival with addition of antitoxin to antimicrobial 
therapy was suggested, but was not demonstrated statistically. This may be due to the small 
sample size; many animals did not survive long enough to receive delayed treatment.27,42 
While antimicrobials prevent bacterial replication, they do not prevent the uptake of toxin 
and the subsequent formation of toxin complexes.18,46,48,52 There is a biologically plausible 
conceptual basis to support antitoxin use in addition to antimicrobial therapy—to prevent 
intracellular uptake of circulating toxin. Antitoxin appears safe and well tolerated,18,32,52 
and thus the benefits appear to outweigh the risks.
In animal studies in which any therapy was delayed, data suggest combined antimicrobial-
antitoxin therapy improves survival compared to antimicrobial therapy alone. However, 
specific clinical predictors that define the greatest likelihood of survival are not known in 
animals or in humans. All 3 human cases of inhalation anthrax received antitoxin treatment 
after clinical signs of sepsis and the initiation of mechanical ventilation. Two of these 
patients survived; the nonsurvivor’s clinical findings may provide important insights. 
Despite a similar timeframe for receipt of antitoxin (ie, from day 6 to day 9 post–symptom 
onset), the nonsurvivor developed respiratory distress earlier in the course of illness. He 
remained in critical condition, required multiorgan support after antitoxin administration, 
and ultimately died 2 weeks post–symptom onset.43,44 Many factors may have contributed 
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to this poor outcome: Extrinsic factors such as large inoculum of inhaled spores or intrinsic 
factors such as individual immunologic and physiologic differences may have resulted in 
more severe disease. There may also be a time point in disease progression after which 
intracellular damage is irrevocable. The low serum lethal factor measurement obtained 6 
days post–antimicrobial initiation in the nonsurvivor may support this notion. The low value 
may indicate an accumulation of toxin intracellularly, and thus further blockade of toxin 
translocation may not have enhanced survival. Intracellular toxin is not affected by the 
administration of antitoxin; therefore, there might be a yet-to-be determined point in illness 
where addition of antitoxin may not improve survival.
For the 2 survivors who received antitoxin treatment, we are unable to disentangle whether 
antitoxin, pleural fluid drainage, intensive supportive care, combination or high-dose 
antimicrobial treatment, or, more likely, a combination of these therapies, was associated 
with survival. Additionally, the impact of endogenous antibody formation prior to antitoxin 
administration is unknown.46,48 In animal studies of severe anthrax disease, antitoxin-
vasopressor combinations were found to improve survival, suggesting an additive effect of 
antitoxin is possible even in patients with vasomotor instability.53
There is limited evidence to guide the judicious use of antitoxin in a large-scale or mass 
anthrax incident. In non–resource limited settings, CDC recommends antitoxin use for all 
patients with systemic anthrax, which is supported by the findings of this review. However, 
during a large-scale or mass incident, depending on the scope of the event and the number of 
individuals infected, antitoxin may not be available to treat all suspected or confirmed 
anthrax cases. Based on the data compiled in this review, when antitoxin supplies are limited 
it may be reasonable to reserve antitoxin for patients who have not demonstrated an obvious 
clinical benefit from antimicrobials, and for patients who present with more severe illness at 
the onset but who have a reasonable chance of survival. More research is needed to define 
specific clinical criteria for antitoxin treatment in resource-limited settings, particularly to 
identify the clinical threshold beyond which antitoxin therapy may not confer a survival 
benefit. Animal studies designed to target the optimal therapeutic window and real-time 
capture of clinical data from naturally occurring cases of anthrax may provide additional 
insight to guide antitoxin use.
Direct assessment of toxin levels may also inform antitoxin use. Measurement of lethal 
factor, which has been shown to be the earliest indicator of B. anthracis infection, presents 
particular promise.54–57 Edema factor, edema toxin, and lethal toxin assays and real-time 
measurements of protective antigen, anti-PA, and capsular antigen may also be useful.58–60 
Finally, a point-of-care toxin assay may provide a mechanism to monitor antimicrobial or 
antimicrobial-antitoxin treatment response.27,34,46,48
Our review has several limitations. There is a dearth of relevant human data, an inherent 
challenge when studying the treatment of rare and highly fatal diseases. Furthermore, animal 
studies do not capture clinical indices, which, even if available, are difficult to correlate with 
those of humans. However, animal pathophysiology studies may provide information to 
correlate toxin levels with organ dysfunction or failure, which may improve understanding 
of anthrax pathogenesis and treatment. Since our review is limited to English articles, animal 
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studies in other languages may provide additional indirect evidence for antitoxin adjunctive 
therapy. It is not known whether different antitoxin products have different levels of efficacy 
or potency since head-to-head comparison studies were not identified. Lastly, our review is 
subject to publication and reporting biases, which are intrinsic to all systematic reviews.
Conclusions
Despite the paucity of relevant human data, limited animal data suggest that adjunctive 
antitoxin therapy may improve survival. While early initiation of antimicrobial therapy has 
previously been shown to improve survival, adjunctive antitoxin therapy may also have a 
role in enhancing survival, particularly for patients in whom serum toxin accumulation is 
likely, or for whom antimicrobial therapy alone does not provide a cure. Additional 
pathophysiology studies are needed, and a point-of-care assay correlating toxin levels with 
clinical status may provide important information to guide antitoxin use.
Acknowledgments
The authors thank Onnalee Gomez for conducting the searches for this systematic review, Theresa Turski and 
Stefan Katharios-Lanwermeyer for reviewing articles, and the members of the CDC Workgroup on Anthrax 
Clinical Guidelines for providing additional references for our review. This project is funded by the Centers for 
Disease Control and Prevention, Office of Public Health Preparedness and Response.
References
1. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 
42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A. 1993; 90(6):2291–2294. 
[PubMed: 8460135] 
2. US Department of Health and Human Services. [Accessed November 10, 2015] Public Health 
Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan. 
2012. http://www.phe.gov/Preparedness/mcm/phemce/Documents/2014-phemce-sip.pdf
3. Inglesby TV, O’Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, 
Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat 
K. Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated 
recommendations for management. JAMA. 2002; 287(17):2236–2252. [PubMed: 11980524] 
4. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United 
States, 2001: epidemiologic findings. Emerg Infect Dis. 2002; 8(10):1019–1028. [PubMed: 
12396909] 
5. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 
cases reported in the United States. Emerg Infect Dis. 2001; 7(6):933–944. [PubMed: 11747719] 
6. Grabenstein JD. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin Infect Dis. 
2008; 46(1):129–136. [PubMed: 18171228] 
7. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: a 
century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med. 2006; 144(4):270–280. 
[PubMed: 16490913] 
8. Collier RJ, Young JA. Anthrax toxin. Annu Rev Cell Dev Biol. 2003; 19:45–70. [PubMed: 
14570563] 
9. Mourez M. Anthrax toxins. Rev Physiol Biochem Pharmacol. 2004; 152:135–164. [PubMed: 
15549606] 
10. Kummerfeldt CE. Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug 
Resist. 2014; 7:101–109. [PubMed: 24812521] 
11. Brossier F, Mock M. Toxins of Bacillus anthracis. Toxicon. 2001; 39(11):1747–1755. [PubMed: 
11595637] 
Huang et al. Page 9













12. Baillie LW. Past, imminent and future human medical countermeasures for anthrax. J Appl 
Microbiol. 2006; 101(3):594–606. [PubMed: 16907809] 
13. Chitlaru T, Altbourn Z, Reuveny S, Shafferman A. Progress and novel strategies in vaccine 
development and treatment of anthrax. Immunol Rev. 2011; 239(1):221–236. [PubMed: 
21198675] 
14. Rainey GJ, Young JA. Antitoxins: novel strategies to target agents of bioterrorism. Nat Rev 
Microbiol. 2004; 2(9):721–726. [PubMed: 15372082] 
15. Schneemann A, Manchester M. Anti-toxin antibodies in prophylaxis and treatment of inhalation 
anthrax. Future Microbiol. 2009; 4(1):35–43. [PubMed: 19207098] 
16. US Food and Drug Administration; Dec 14. 2012 FDA approves raxibacumab to treat inhalational 
anthrax [news release]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm332341.htm [Accessed November 10, 2015]
17. US Food and Drug Administration; Mar 25. 2015 FDA approves treatment for inhalation anthrax 
[news release]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm439752.htm [Accessed November 10, 2015]
18. Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, 
Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA. Workgroup on Anthrax 
Clinical Guidelines. Centers for Disease Control and Prevention expert panel meetings on 
prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014; 20(2)
19. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):
1006–1012. [PubMed: 19631508] 
20. [Accessed November 10, 2015] Pathway to Licensure for Protective Antigen-based Anthrax 




21. Committee on Animal Models for Assessing Countermeasures to Bioterrorism Agents; National 
Research Council. Animal Models for Assessing Countermeasures to Bioterrorism Agents. 
Washington, DC: National Academies Press; 2011. 
22. Phipps AJ, Premanandan C, Barnewall RE, Lairmore MD. Rabbit and nonhuman primate models 
of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev. 2004; 68(4):617–629. 
[PubMed: 15590776] 
23. Comer JE, Ray BD, Henning LN, Stark GV, Barnewall RE, Mott JM, Meister GT. 
Characterization of a therapeutic model of inhalational anthrax using an increase in body 
temperature in New Zealand white rabbits as a trigger for treatment. Clin Vaccine Immunol. 2012; 
19(9):1517–1525. [PubMed: 22837095] 
24. Henning LN, Comer JE, Stark GV, et al. Development of an inhalational Bacillus anthracis 
exposure therapeutic model in cynomolgus macaques. Clin Vaccine Immunol. 2012; 19(11):1765–
1775. [PubMed: 22956657] 
25. Twenhafel NA. Pathology of inhalational anthrax animal models. Vet Pathol. 2010; 47(5):819–
830. [PubMed: 20656900] 
26. Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational 
anthrax. N Engl J Med. 2009; 361(2):135–144. [PubMed: 19587338] 
27. Kammanadiminti S, Patnaikuni RK, Comer J, Meister G, Sinclair C, Kodihalli S. Combination 
therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more 
effective than antibiotics alone in rabbit model of inhalational anthrax. PLoS One. 2014; 
9(9):e106393. [PubMed: 25226075] 
28. Meaney-Delman D, Zotti ME, Rasmussen SA, et al. Anthrax cases in pregnant and postpartum 
women: a systematic review. Obstet Gynecol. 2012; 120(6):1439–1449. [PubMed: 23168771] 
29. Human Genome Sciences, Inc. [Accessed November 10, 2015] Anti-Infective Drugs Advisory 
Committee Meeting: Raxibacumab, Treatment of Inhalational Anthrax, BLA 125349. Nov 2. 2012 
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-
InfectiveDrugsAdvisoryCommittee/UCM326185.pdf
Huang et al. Page 10













30. Malkevich NV, Hopkins RJ, Bernton E, et al. Efficacy and safety of AVP-21D9, an anthrax 
monoclonal antibody, in animal models and humans. Antimicrob Agents Chemother. 2014; 58(7):
3618–3625. [PubMed: 24733473] 
31. Mytle N, Hopkins RJ, Malkevich NV, et al. Evaluation of intravenous anthrax immune globulin for 
treatment of inhalation anthrax. Antimicrob Agents Chemother. 2013; 57(11):5684–5692. 
[PubMed: 23979731] 
32. [Accessed November 10, 2015] Clinical Pharmacology BLA Review; Division of Hematology, 
Office of Blood Review and Research. Jul 25. 2014 http://www.fda.gov/downloads/
BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM443660.pdf
33. ANTHRASIL/Anthrax Immune Globulin Intravenous (Human). Cangene Corporation; Mar 25. 
2015 Summary Basis for Regulatory Action. http://www.fda.gov/downloads/
BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/
FractionatedPlasmaProducts/UCM443728.pdf [Accessed November 10, 2015]
34. Elusys Therapeutics, Inc. [Accessed November 10, 2015] Elusys releases new data on anthrax anti-
toxin administered via intramuscular injection from three recent animal studies [news release]. Jul 
31. 2013 http://www.prnewswire.com/news-releases/elusys-releases-new-data-on-anthrax-anti-
toxin-administered-via-intramuscular-injection-from-three-recent-animal-studies-217754071.html
35. Beebe, LB.; Barnewall, R.; Zhong, J.; Choi, G. Post-exposure therapeutic potential of PAmAb in 
an inhalation model of anthrax in New Zealand white rabbits. Presented at: American Society of 
Microbiology Biodefense Meeting; March 2004; Baltimore, MD. 
36. Mazumdar S. Raxibacumab. MAbs. 2009; 1(6):531–538. [PubMed: 20068396] 
37. Mohamed N, Clagett M, Li J, et al. A high-affinity monoclonal antibody to anthrax protective 
antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. 
Infect Immun. 2005; 73(2):795–802. [PubMed: 15664918] 
38. Peterson JW, Comer JE, Baze WB, et al. Human monoclonal antibody AVP-21D9 to protective 
antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit 
model. Infect Immun. 2007; 75(7):3414–3424. [PubMed: 17452469] 
39. Peterson JW, Comer JE, Noffsinger DM, et al. Human monoclonal anti-protective antigen antibody 
completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea 
pigs against inhalation anthrax. Infect Immun. 2006; 74(2):1016–1024. [PubMed: 16428748] 
40. Vitale L, Blanset D, Lowy I, et al. Prophylaxis and therapy of inhalational anthrax by a novel 
monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun. 
2006; 74(10):5840–5847. [PubMed: 16988263] 
41. Biron B, Beck K, Dyer D, Mattix M, Twenhafel N, Nalca A. Efficacy of ETI-204 monoclonal 
antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for 
inhalational anthrax. Antimicrob Agents Chemother. 2015; 59(4):2206–2214. [PubMed: 
25645849] 
42. Corey A, Migone TS, Bolmer S, et al. Bacillus anthracis protective antigen kinetics in inhalation 
spore-challenged untreated or levofloxacin/raxibacumab-treated New Zealand white rabbits. 
Toxins (Basel). 2013; 5(1):120–138. [PubMed: 23344456] 
43. A single case of inhalation anthrax in a drum maker in London. Health Protection Report. Oct 
31.2008 2(44) http://webarchive.nationalarchives.gov.uk/20140714084352/http://
www.hpa.org.uk/hpr/archives/2008/news4408.htm. 
44. Anaraki S, Addiman S, Nixon G, et al. Investigations and control measures following a case of 
inhalation anthrax in East London in a drum maker and drummer, October 2008. Euro Surveill. 
2008; 13(51):19076. [PubMed: 19094916] 
45. Centers for Disease Control and Prevention. Inhalation anthrax associated with dried animal hides
—Pennsylvania and New York City, 2006. MMWR Morb Mortal Wkly Rep. 2006; 55(10):280–
282. [PubMed: 16543883] 
46. Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: clinical care 
and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis. 2007; 
44(7):968–971. [PubMed: 17342650] 
47. Griffith J, Blaney D, Shadomy S, Lehman M, Pesik N, Tostenson S, Delaney L, Tiller R, DeVries 
A, Gomez T, Sullivan M, Blackmore C, Stanek D, Lynfield R. Anthrax Investigation Team. 
Huang et al. Page 11













Investigation of inhalation anthrax case, United States. Emerg Infect Dis. 2014; 20(2):280–283. 
[PubMed: 24447835] 
48. Sprenkle MD, Griffith J, Marinelli W, et al. Lethal factor and anti-protective antigen IgG levels 
associated with inhalation anthrax, Minnesota, USA. Emerg Infect Dis. 2014; 20(2):310–314. 
[PubMed: 24447456] 
49. Centers for Disease Control and Prevention. E-IND protocol: one time emergency use of liquid 5% 
anthrax immune globulin for treatment of severe anthrax. Centers for Disease Control and 
Prevention; Feb 22. 2006 
50. Boyer, AE. Clinical Utilization Plan for Anthrax Countermeasures in a Mass Event Setting 
Workshop. Centers for Disease Control and Prevention; Atlanta, Georgia: 2014. Prognostic 
indicators, anthrax immune globulin intravenous use and toxin levels in recent systemic anthrax 
cases. 
51. Subramanian GM, Cronin PW, Poley G, et al. A phase 1 study of PAmAb, a fully human 
monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin 
Infect Dis. 2005; 41(1):12–20. [PubMed: 15937757] 
52. Barochia AV, Cui X, Sun J, et al. Protective antigen antibody augments hemodynamic support in 
anthrax lethal toxin shock in canines. J Infect Dis. 2012; 205(5):818–829. [PubMed: 22223857] 
53. Boyer AE, Gallegos-Candela M, Lins RC, et al. Quantitative mass spectrometry for bacterial 
protein toxins—a sensitive, specific, high-throughput tool for detection and diagnosis. Molecules. 
2011; 16(3):2391–2413. [PubMed: 21403598] 
54. Boyer AE, Quinn CP, Beesley CA, et al. Lethal factor toxemia and anti-protective antigen antibody 
activity in naturally acquired cutaneous anthrax. J Infect Dis. 2011; 204(9):1321–1327. [PubMed: 
21908727] 
55. Boyer AE, Quinn CP, Hoffmaster AR, et al. Kinetics of lethal factor and poly-D-glutamic acid 
antigenemia during inhalation anthrax in rhesus macaques. Infect Immun. 2009; 77(8):3432–3441. 
[PubMed: 19506008] 
56. Boyer AE, Quinn CP, Woolfitt AR, et al. Detection and quantification of anthrax lethal factor in 
serum by mass spectrometry. Anal Chem. 2007; 79(22):8463–8470. [PubMed: 17929949] 
57. Fish DC, Lincoln RE. In vivo-produced anthrax toxin. J Bacteriol. 1968; 95(3):919–924. [PubMed: 
4966834] 
58. Kobiler D, Gozes Y, Rosenberg H, Marcus D, Reuveny S, Altboum Z. Efficiency of protection of 
guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect 
Immun. 2002; 70(2):544–550. [PubMed: 11796581] 
59. Rossi CA, Ulrich M, Norris S, Reed DS, Pitt LM, Leffel EK. Identification of a surrogate marker 
for infection in the African green monkey model of inhalation anthrax. Infect Immun. 2008; 
76(12):5790–5801. [PubMed: 18852240] 
Huang et al. Page 12















Huang et al. Page 13














Flow Diagram of Search Strategy
Huang et al. Page 14










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Health Secur. Author manuscript; available in PMC 2016 November 01.
